Pre-IND meeting: how to request it and write questions that head off a clinical hold

At a glance

• A pre-IND meeting is a meeting a sponsor requests with FDA before submitting the initial IND. Part 312 names it in Subpart E, for drugs that treat life-threatening or severely debilitating illnesses, as a meeting to agree on the animal studies needed to start human testing.
• No section of Part 312 requires a pre-IND meeting before an IND is filed. The sponsor may request one, and on request FDA will advise on specific IND matters such as the adequacy of technical data and trial design.
• FDA’s formal-meetings guidance (final, August 2026) classes the pre-IND meeting as a Type B meeting: FDA answers the request within 21 days and schedules the meeting within 60 days, and the package is due at least 30 days before. These are guidance timelines, not regulation.
• Under the guidance, FDA may answer a pre-IND request in writing only, whatever format the sponsor asked for, and should receive no more than 10 questions including subquestions.
• The best questions map to the IND content FDA will review under 312.23 and to the clinical hold grounds in 312.42(b), and are phrased so FDA can agree or disagree.

A pre-IND meeting is the sponsor’s chance to put its development plan in front of the FDA review division before the IND is filed. Thirty days after FDA receives an IND, the investigations either may begin or are on clinical hold, and the meeting is where a sponsor can find out in advance which parts of the plan FDA would object to. This guide separates the regulation from FDA guidance, then covers the request, the questions and the briefing package.

What the regulation says, and what guidance adds

The regulation says less about pre-IND meetings than most guides suggest. Three provisions matter.

312.82(a), the only place Part 312 names the meeting. For products intended to treat life-threatening or severely debilitating illnesses, the sponsor may request a meeting with FDA reviewing officials before submitting the initial IND (312.82(a)). Its primary purpose is to review and reach agreement on the design of animal studies needed to start human testing, and it may also cover the scope and design of Phase 1, plans for pediatric studies, and how to present and format data in the IND (312.82(a)). Subpart E applies to new drugs and biologics studied for treating life-threatening or severely debilitating diseases (312.81).

312.47(a), meetings in general. FDA encourages meetings with sponsors to the extent that they aid evaluation of the drug and solve scientific problems, to the extent FDA’s resources permit, and the meetings must be conducted and documented under Part 10 (312.47(a)). The section goes on to name end-of-Phase 2 and pre-NDA meetings, but not pre-IND meetings (312.47(b)).

312.41(b), advice on request. On the sponsor’s request, FDA will advise on specific matters relating to an IND, such as the adequacy of technical data to support an investigational plan and the design of a clinical trial (312.41(b)). Unless accompanied by a clinical hold order, FDA’s communications under 312.41 are solely advisory and do not require any change to planned or ongoing investigations (312.41(c)).

FDA’s guidance Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products (final, August 2026) supplies the procedure: meeting types, request contents, formats, timelines, preliminary responses and minutes. It covers drugs and biologics regulated by CDER and CBER, and its list of Type B meetings includes pre-IND meetings without limiting them to Subpart E products. The guidance says it is not binding on FDA or the public and does not establish legally enforceable responsibilities. Every timeline below comes from it, so check the numbers against the version current when you plan.

The two documents do not describe the same meeting. The regulation names the pre-IND meeting only for life-threatening and severely debilitating illnesses, and frames its purpose around animal studies. The guidance makes it a Type B meeting for any CDER or CBER product in its scope. A sponsor outside Subpart E is relying on the guidance and on 312.41(b), not on 312.82(a).

Do you need one?

No section of Part 312 requires one. The sponsor must submit an IND before a clinical investigation subject to Part 312, and must not begin until the IND is in effect (312.20). The pre-IND meeting is something the sponsor may request (312.82(a)).

It earns its preparation time when FDA’s view could change the IND itself:

• A first study in humans of a new molecule, where the toxicology package and the starting dose are judgment calls.
• A novel modality that FDA guidance does not yet cover on the nonclinical or manufacturing side.
• A small biotech or academic sponsor with thin data. The amount of information an IND needs depends on the novelty of the drug, how far it has been studied, the known or suspected risks, and the phase (312.22(b)). A sponsor-investigator using a drug not subject to a manufacturer’s IND or marketing application ordinarily must submit all the technical information, unless it can be referenced from the scientific literature (312.22(d)). Whether literature can stand in for a toxicology study is exactly the kind of question to settle in advance. The investigator-initiated trials guide covers the sponsor-investigator role more broadly.
• A study that may not need an IND at all. On request, FDA will advise on whether Part 312 applies to a planned investigation (312.2(e)). Our guide to IND exemptions covers the conditions.

A sponsor using a well-characterised drug in a conventional Phase 1 design may reasonably file without one. Most of the effort goes into writing a package good enough to get useful answers, so weigh that against what FDA’s view would change.

INTERACT, pre-IND, or straight to the IND

Route	What it is for	When	Timeline in FDA’s guidance
INTERACT meeting (sometimes called pre-pre-IND)	Novel products or programs with a challenging issue that could delay first-in-human testing, such as the design of toxicology studies or complex manufacturing	Before a pre-IND meeting, with a specific product or derivation strategy already selected	FDA answers the request within 21 days and schedules within 75 days. The package goes in with the request
Pre-IND meeting (Type B)	Agreement on the nonclinical, manufacturing and clinical plan for the IND	Before the initial IND	FDA answers the request within 21 days and schedules within 60 days. The package is due no later than 30 days before the meeting
No meeting	A conventional program where FDA’s view is predictable	File the IND directly	The 30-day review in 312.40(b)

The guidance says INTERACT is not the right meeting type once a requester has had a pre-IND meeting or filed an IND. It also says that, except for breakthrough therapy and RMAT-designated products, FDA generally will not grant more than one of each Type B meeting per potential application. In practice a sponsor gets one pre-IND meeting, so hold it when the plan is settled enough to ask about.

The request: what goes in it

The guidance splits the request into items it must include and items it should include. Adapted to a pre-IND request, the outline is:

1. The product name(s), chemical name and structure where appropriate, the proposed indication, and the proposed regulatory pathway (for example 505(b)(1), 505(b)(2) or a 351(a) BLA). The application number if one has been assigned.
2. The meeting type, Type B (pre-IND), and the format you want: hybrid in-person, video conference, teleconference or written response only. The format is a required item.
3. A short statement of what the meeting is for, a summary of completed and planned studies, and where the meeting fits in the development plan. Enough for FDA to understand the issues, such as a table of major results, without full study detail. Required.
4. The specific objectives or outcomes you expect from the meeting.
5. A proposed agenda, with estimated time per item. Required.
6. Your attendees (names, titles, affiliations, consultants and interpreters) and the FDA attendees or disciplines you want present. Both lists are required.
7. The date the meeting package will be sent. Required.
8. Proposed dates within the Type B scheduling window, and dates you are not available.
9. The questions, grouped by FDA discipline, each with a short note on context and purpose. Pediatric study plans, a human factors plan and combination product details go in too where they apply.

The guidance recommends no more than 10 questions in total, with every subquestion given its own number: three parts to one question become questions 1, 2 and 3, not 1a, 1b and 1c. Requests go to the review division through the electronic gateway or, in CDER, the CDER NextGen Portal, and noncommercial IND holders may use the center’s document room if necessary.

For a pre-IND meeting, the format you ask for may not be the one you get. The guidance’s Table 3 sorts meeting types into two groups. For Type A, Type B (EOP) and every Type B meeting except pre-IND, FDA grants a written response only if the requester asked for one. For pre-IND, Type C, Type D and INTERACT, FDA may grant a written response only, if appropriate, whatever format was requested. A sponsor who believes a live meeting is needed can send the division its reasons in follow-up correspondence, and FDA will consider changing the format. The written response arrives on the same 60-day clock as a Type B meeting would.

The regulation reads differently. Section 312.82 says that, to the extent FDA resources permit, reviewing officials will honor requests for early-consultation meetings, and 312.82(a) describes the pre-IND meeting as a meeting. The guidance lets FDA answer the same request on paper. The two texts are not aligned, and a Subpart E sponsor who wants a discussion should expect to make the case for one.

Writing questions FDA can answer

A question FDA can answer yes or no is worth more than a request for general feedback. Build each one from the IND content FDA will review and the ground on which it could put the IND on hold.

The hold grounds are in the regulation. FDA may place a Phase 1 investigation on clinical hold if subjects would be exposed to an unreasonable and significant risk of illness or injury, if the investigators are not qualified, if the investigator brochure is misleading, erroneous or materially incomplete, or if the IND does not contain enough of the information required under 312.23 to assess the risks to subjects (312.42(b)(1)). For Phase 2 or 3, FDA may also impose a hold if the protocol is clearly deficient in design to meet its stated objectives (312.42(b)(2)).

IND content area (312.23)	Hold ground it protects against	Weak question	Strong question
Pharmacology and toxicology (312.23(a)(8))	Unreasonable and significant risk (312.42(b)(1)(i)), insufficient information (312.42(b)(1)(iv))	“Does FDA have comments on our nonclinical program?"	"Does FDA agree that the 28-day GLP studies in rat and dog described in section 4 support single and multiple ascending doses up to 14 days?”
Chemistry, manufacturing and control (312.23(a)(7))	Insufficient information to assess risk (312.42(b)(1)(iv))	“Is our CMC adequate?"	"Does FDA agree that the drug substance specifications and the 3-month stability data in section 5 are sufficient for a Phase 1 study of up to 28 days?”
Protocol (312.23(a)(6))	Unreasonable and significant risk (312.42(b)(1)(i))	“Please comment on our Phase 1 design."	"Does FDA agree with the starting dose of X mg, derived as shown in section 6, and with the dose-escalation stopping rules in the synopsis?”
Investigator’s brochure (312.23(a)(5))	Misleading, erroneous or materially incomplete brochure (312.42(b)(1)(iii))	“Is our IB acceptable?"	"Does FDA agree that the risks section of the draft IB covers the findings from the toxicology studies summarised in section 4?”
Previous human experience (312.23(a)(9))	Insufficient information (312.42(b)(1)(iv))	“Can we use published data?"	"Does FDA agree that the published human data listed in appendix B can support the safety of the proposed dose range, in place of a separate study?”
Phase 2 or 3 protocol (312.23(a)(6)(ii))	Protocol clearly deficient in design (312.42(b)(2)(ii))	“Is our endpoint acceptable?"	"Does FDA agree that endpoint Y, measured at week 12, is an acceptable primary endpoint for this population?”

The figures in the strong column are placeholders for your program’s own. Each strong question names the data, names the decision, and asks whether FDA agrees. With a cap of 10 numbered questions, six rows like these leave room for four more, so spend them on the areas where a hold is most likely.

What the regulation expects at Phase 1 helps you set the scope of those questions. In an initial Phase 1 submission, the emphasis for CMC is generally on identifying and controlling the raw materials and the new drug substance, and final specifications are not expected until the end of the investigational process (312.23(a)(7)(i)). The Phase 1 manufacturing guide covers what that means for Phase 1 material. The pharmacology and toxicology section must contain enough information for the sponsor to have concluded that it is reasonably safe to conduct the proposed investigations (312.23(a)(8)). Efficacy-design questions, such as the estimand and the statistical analysis plan, belong to later meetings and to separate guides.

The briefing package

The guidance calls it the meeting package and asks for it to be organised by the agenda, sequentially paginated, with a linked table of contents. It repeats the items from the request and adds the following, preferably in this order:

1. Attendee list: names, titles and affiliations, including consultants and interpreters.
2. Background: a brief history of the program and any earlier FDA contact, any substantive changes to the plan, and the current development status.
3. Purpose and meeting type.
4. Proposed agenda.
5. The final questions, up to 10 in total, grouped by discipline, each with a short explanation of why you are asking it. Keep the numbering the same as in the request.
6. Supporting data by discipline and question. The guidance asks for summaries with some degree of quantification and says protocols, full study reports and detailed data generally don’t belong. For a pre-IND package that usually means:
   • CMC: drug substance and drug product description, manufacturing summary, specifications and stability to date.
   • Pharmacology and toxicology: study designs, species, durations, findings and the proposed safety margins.
   • Clinical: the Phase 1 protocol synopsis, starting-dose rationale, stopping rules and monitoring plan.
   • Regulatory: the proposed pathway and any departures from FDA guidance, explained.

The guidance asks sponsors to identify and explain any place where the plan departs from current guidance or precedent. If you plan to rely on literature in place of a study, say so in the package and ask about it directly.

Under the guidance, a Type B package must reach FDA no later than 30 days before the meeting date, or before the written response date. The guidance lists a package that arrives late, or is grossly inadequate, as a reason FDA can cancel the meeting, and a cancelled meeting needs a new request on a new clock.

After the meeting: minutes and carrying agreements into the IND

For Type A and Type B meetings other than end-of-phase meetings, the guidance says FDA intends to send preliminary responses no later than 2 calendar days before the meeting. If they answer everything, ask the FDA project manager to cancel. If FDA agrees, the preliminary responses become the final responses and the official record. Presentations at the meeting itself are usually unnecessary, because the package should already carry the information. FDA policy prohibits audio or visual recording, so take your own notes.

FDA’s minutes are the official record and arrive within 30 calendar days. They list agreements, disagreements, open issues and action items, and they can include points FDA did not raise in the room, marked as such. If FDA answered in writing only, that written response is the minutes. To confirm what the advice means, send a Request for Clarification within 20 calendar days of receiving the minutes or written response, limited to clarifying questions, and FDA will reply in writing within 20 calendar days. A new issue needs a new request.

The minutes need to reach the IND. Reference them in the IND’s introductory statement or cover letter, and show where the IND follows each agreement. The IND itself goes in under a Form FDA 1571 cover sheet, and what it must contain is covered in the FDA IND application.

Two limits apply. The regulation does not make pre-IND agreements binding. The binding-style language in 312.47(b)(1) applies to end-of-Phase 2 agreements, where studies conducted under the agreement are presumed sufficient barring a significant scientific development (312.47(b)(1)). And FDA’s advice is advisory unless a clinical hold order comes with it (312.41(c)). The guidance calls the minutes the official record, but that does not give a pre-IND agreement the presumption the regulation gives an end-of-Phase 2 agreement. A pre-IND meeting reduces hold risk but does not remove it. Before imposing a hold, FDA will try to discuss and resolve the deficiency with the sponsor unless patients face immediate and serious risk (312.42(c)). What happens if a hold comes anyway is covered in our guide to FDA clinical holds. If you disagree with the division later, 312.48 sets out the dispute resolution route. For where the pre-IND meeting sits in Part 312 as a whole, see the 21 CFR 312 map.

Sources

• 21 CFR Part 312, Investigational New Drug Application, eCFR text up to date as of 14 April 2026
• FDA guidance: Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products, final, August 2026